As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Pulse Biosciences, Inc. The largest reported stake is Robert W. Duggan's, at 71.9%. One filing is on record since May 13, 2026 (Schedule 13D/A, May 13, 2026).
Sell to companies like Pulse Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Robert W. Duggan · Sole voting: 49,706,423 · Shared voting: 0 · Sole dispositive: 49,706,423 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-05-13
- · Reporting person: Genius 24c Inc · Sole voting: 630,109 · Shared voting: 0 · Sole dispositive: 630,109 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-05-13
- · Reporting person: Blazon Corporation · Sole voting: 450,189 · Shared voting: 0 · Sole dispositive: 450,189 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-05-13
- · Holder: Robert W. Duggan · Percent: 71.9% · SCHEDULE 13D/A
- · Holder: Robert W. Duggan · Percent: 71.9% · Shares: 49,706,423 · SCHEDULE 13D/A
Pulse Biosciences, Inc. has 1 Schedule 13D or 13G filing on record since 2026-05-13. 1 holder's latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 71.9% | 49,706,423 | SCHEDULE 13D/A, 2026-05-13 | 2026-05-11 |
Holding shares or following this stake? See who's behind Pulse Biosciences, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Pulse Biosciences, Inc. and the records around it.
Pulse Biosciences, Inc. elsewhere on the record
- Leadership changes Apr 2026
Watch Pulse Biosciences, Inc.
Get an email when Pulse Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Pulse Biosciences, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Pulse Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Pulse Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Robert W. Duggan | 49,706,423 | 0 | 49,706,423 | 0 | SCHEDULE 13D/A, 2026-05-13 |
| Genius 24c Inc | 630,109 | 0 | 630,109 | 0 | SCHEDULE 13D/A, 2026-05-13 |
| Blazon Corporation | 450,189 | 0 | 450,189 | 0 | SCHEDULE 13D/A, 2026-05-13 |
The latest filing identifies Pulse Biosciences, Inc. by CUSIP 74587B101 and gives its principal executive office as 601 Brickell Key Drive, Suite 1080, Miami, FL 33131 (SCHEDULE 13D/A, 2026-05-13).
Source of funds (Item 3)
Item 3 is hereby amended and restated to read as follows: The aggregate purchase cost of the 49,706,423 shares of common stock beneficially owned by Mr. Duggan is approximately $414,666,603 including brokerage commissions. Such shares were acquired with personal funds (with the exception of the 630,109 shares owned Genius 24C Inc d/b/a Genius Inc and the 450,189 shares owned by Blazon Corporation. Mr. Duggan received his 256,078 stock options in connection with his service on the board of directors of the Issuer).Robert W. Duggan, SCHEDULE 13D/A, 2026-05-13
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-05-13 | Robert W. Duggan | 71.9% | SCHEDULE 13D/A |
Also on the record for Pulse Biosciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| April 9, 2026 | Leadership change: Liane R. Teplitsky appointed, Chief Operating Officer | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Pulse Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.